Canadian Journal of Cardiology

Coronary Revascularization in Patients With Advanced Chronic Kidney Disease

Published:April 19, 2019DOI:


      Patients with chronic kidney disease (CKD) have an increased risk of obstructive coronary artery disease (CAD), whereas patients with end stage renal disease who are receiving hemodialysis represent a population at particularly high risk of developing cardiac ischemic events. Patients with CKD and acute coronary syndromes should be treated the same way as acute coronary syndromes patients without kidney dysfunction. The benefit of revascularization in patients with advanced kidney failure and CAD is unknown. Observational studies suggest that revascularization might confer a survival benefit compared with medical therapy alone. Little evidence from randomized trials exists regarding the effectiveness of revascularization of patients with CAD with either coronary artery bypass grafting or percutaneous coronary intervention vs medical therapy alone in patients with CKD. The risk of contrast-induced nephropathy is a major concern when percutaneous coronary intervention is performed in patients with CKD. Strict rehydration protocols and techniques to minimize contrast use are paramount to reduce this risk. Finally, in CKD patients who are awaiting kidney transplantation, a noninvasive or invasive CAD screening approach according to the cardiovascular risk profile should be used. Revascularization should be performed in candidates with critical lesions.


      Les patients atteints de néphropathie chronique (NC) présentent un risque accru de coronaropathie obstructive, tandis que les patients atteints de néphropathie terminale sous hémodialyse présentent un risque particulièrement élevé d’ischémie cardiaque. Les patients atteints de NC et d’un syndrome coronarien aigu doivent recevoir le même traitement que les patients atteints d’un syndrome coronarien aigu sans insuffisance rénale. Les bienfaits de la revascularisation chez les patients atteints d’insuffisance rénale à un stade avancé et de coronaropathie ne sont pas connus. Des études d’observation indiquent que la revascularisation pourrait améliorer la survie comparativement à un traitement médical administré seul. Il existe peu de données probantes provenant d’essais avec répartition aléatoire concernant l’efficacité de la revascularisation chez les patients atteints de coronaropathie qui ont subi un pontage aortocoronarien ou une intervention coronarienne percutanée comparativement aux patients atteints de NC ayant reçu un traitement médical seulement. Le risque de néphropathie induite par un agent de contraste est élevé chez les patients atteints de NC subissant une intervention coronarienne percutanée. Des protocoles et des techniques de réhydratation rigoureux visant à minimiser l’emploi d’agents de contraste sont essentiels pour réduire ce risque. Enfin, chez les patients atteints de NC qui sont en attente d’une greffe de rein, le dépistage de la coronaropathie par une méthode invasive ou non invasive, en fonction du profil de risque cardiovasculaire, est recommandé. Une revascularisation s’impose chez les patients présentant des lésions critiques.
      To read this article in full you will need to make a payment

      Purchase one-time access:

      Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online access
      One-time access price info
      • For academic or personal research use, select 'Academic and Personal'
      • For corporate R&D use, select 'Corporate R&D Professionals'


      Subscribe to Canadian Journal of Cardiology
      Already a print subscriber? Claim online access
      Already an online subscriber? Sign in
      Institutional Access: Sign in to ScienceDirect


        • Chonchol M.
        • Whittle J.
        • Desbien A.
        • et al.
        Chronic kidney disease is associated with angiographic coronary artery disease.
        Am J Nephrol. 2008; 28: 354-360
      1. Chapter 1: Definition and classification of CKD.
        Kidney Int Suppl (2011). 2013; 3: 19-62
        • Go A.S.
        • Chertow G.M.
        • Fan D.
        • McCulloch C.E.
        • Hsu C.Y.
        Chronic kidney disease and the risks of death, cardiovascular events, and hospitalization.
        N Engl J Med. 2004; 351: 1296-1305
        • Thompson S.
        • James M.
        • Wiebe N.
        • et al.
        Cause of death in patients with reduced kidney function.
        J Am Soc Nephrol. 2015; 26: 2504-2511
        • Pun P.H.
        • Smarz T.R.
        • Honeycutt E.F.
        • et al.
        Chronic kidney disease is associated with increased risk of sudden cardiac death among patients with coronary artery disease.
        Kidney Int. 2009; 76: 652-658
        • Matsushita K.
        • Coresh J.
        • Sang Y.
        • et al.
        Estimated glomerular filtration rate and albuminuria for prediction of cardiovascular outcomes: a collaborative meta-analysis of individual participant data.
        Lancet Diabetes Endocrinol. 2015; 3: 514-525
      2. KDIGO 2012 Clinical Practice Guideline for the Evaluation and Management of Chronic Kidney Disease.
        Kidney Int Suppl. 2013; 3: 1
        • Collins A.J.
        • Foley R.N.
        • Chavers B.
        • et al.
        US renal data system 2013 annual data report: preface.
        Am J Kidney Dis. 2014; 63: A7
        • Shroff G.R.
        • Li S.
        • Herzog C.A.
        Trends in mortality following acute myocardial infarction among dialysis patients in the United States over 15 years.
        J Am Heart Assoc. 2015; 4e002460
        • 30-Day Acute Myocardial Infarction in-Hospital Mortality
        The Risk-Adjusted Rate of All-Cause in-Hospital Death Occurring Within 30 Days of First Discharge From an Acute Care Hospital With a Diagnosis of Acute Myocardial Infarction (AMI).
        Canadian Institute for Health Information, 2015 (Available at:) (Accessed July 13, 2019)
        • Schwarz U.
        • Buzello M.
        • Ritz E.
        • et al.
        Morphology of coronary atherosclerotic lesions in patients with end-stage renal failure.
        Nephrol Dial Transplant. 2000; 15: 218-223
        • Coskun U.
        • Orta Kilickesmez K.
        • Abaci O.
        • et al.
        The relationship between chronic kidney disease and SYNTAX score.
        Angiology. 2011; 62: 504-508
        • Osten M.D.
        • Ivanov J.
        • Eichhofer J.
        • et al.
        Impact of renal insufficiency on angiographic, procedural, and in-hospital outcomes following percutaneous coronary intervention.
        Am J Cardiol. 2008; 101: 780-785
        • Attallah N.
        • Yassine L.
        • Fisher K.
        • Yee J.
        Risk of bleeding and restenosis among chronic kidney disease patients undergoing percutaneous coronary intervention.
        Clin Nephrol. 2005; 64: 412-418
        • Jalal D.I.
        • Chonchol M.
        • Targher G.
        Disorders of hemostasis associated with chronic kidney disease.
        Semin Thromb Hemost. 2010; 36: 34-40
        • Sedlis S.P.
        • Jurkovitz C.T.
        • Hartigan P.M.
        • et al.
        Optimal medical therapy with or without percutaneous coronary intervention for patients with stable coronary artery disease and chronic kidney disease.
        Am J Cardiol. 2009; 104: 1647-1653
        • Hemmelgarn B.R.
        • Southern D.
        • Culleton B.F.
        • et al.
        Survival after coronary revascularization among patients with kidney disease.
        Circulation. 2004; 110: 1890-1895
        • Chan M.Y.
        • Becker R.C.
        • Sim L.L.
        • et al.
        Reperfusion strategy and mortality in ST-elevation myocardial infarction among patients with and without impaired renal function.
        Ann Acad Med Singapore. 2010; 39: 179-184
        • Charytan D.M.
        • Wallentin L.
        • Lagerqvist B.
        • et al.
        Early angiography in patients with chronic kidney disease: a collaborative systematic review.
        Clin J Am Soc Nephrol. 2009; 4: 1032-1043
        • Chertow G.M.
        • Normand S.L.
        • Silva L.R.
        • McNeil B.J.
        Survival after acute myocardial infarction in patients with end-stage renal disease: results from the cooperative cardiovascular project.
        Am J Kidney Dis. 2000; 35: 1044-1051
        • Dragu R.
        • Behar S.
        • Sandach A.
        • et al.
        Should primary percutaneous coronary intervention be the preferred method of reperfusion therapy for patients with renal failure and ST-elevation acute myocardial infarction?.
        Am J Cardiol. 2006; 97: 1142-1145
        • Eisenstein E.L.
        • Sun J.L.
        • Anstrom K.J.
        • et al.
        Assessing the economic attractiveness of coronary artery revascularization in chronic kidney disease patients.
        J Med Syst. 2009; 33: 287-297
        • Keeley E.C.
        • Kadakia R.
        • Soman S.
        • Borzak S.
        • McCullough P.A.
        Analysis of long-term survival after revascularization in patients with chronic kidney disease presenting with acute coronary syndromes.
        Am J Cardiol. 2003; 92: 509-514
        • Yasuda K.
        Comparison of percutaneous coronary intervention with medication in the treatment of coronary artery disease in hemodialysis patients.
        J Am Soc Nephrol. 2006; 17: 2322-2332
        • Volodarskiy A.
        • Kumar S.
        • Amin S.
        • Bangalore S.
        Optimal treatment strategies in patients with chronic kidney disease and coronary artery disease.
        Am J Med. 2016; 129: 1288-1298
        • Bangalore S.
        • Maron D.J.
        • Fleg J.L.
        • et al.
        International Study of Comparative Health Effectiveness with Medical and Invasive Approaches–Chronic Kidney Disease (ISCHEMIA-CKD): rationale and design.
        Am Heart J. 2018; 205: 42-52
        • Best P.J.M.
        • Lennon R.
        • Ting H.H.
        • et al.
        The impact of renal insufficiency on clinical outcomes in patients undergoing percutaneous coronary interventions.
        J Am Coll Cardiol. 2002; 39: 1113-1119
        • Appleby C.E.
        • Ivanov J.
        • Lavi S.
        • et al.
        The adverse long-term impact of renal impairment in patients undergoing percutaneous coronary intervention in the drug-eluting stent era.
        Circ Cardiovasc Interv. 2009; 2: 309-316
        • Wright R.S.
        • Reeder G.S.
        • Herzog C.A.
        • et al.
        Acute myocardial infarction and renal dysfunction: a high-risk combination.
        Ann Intern Med. 2002; 137: 563
        • Charytan D.
        • Mauri L.
        • Agarwal A.
        • et al.
        The use of invasive cardiac procedures after acute myocardial infarction in long-term dialysis patients.
        Am Heart J. 2006; 152: 558-564
        • Szummer K.
        • Lundman P.
        • Jacobson S.H.
        • et al.
        Influence of renal function on the effects of early revascularization in non-st-elevation myocardial infarction: data from the Swedish Web-system for enhancement and development of evidence-based care in heart disease evaluated according to recommended therapies (SWEDEHEART).
        Circulation. 2009; 120: 851-858
        • James M.T.
        • Tonelli M.
        • Ghali W.A.
        • et al.
        Renal outcomes associated with invasive vs conservative management of acute coronary syndrome: propensity matched cohort study.
        BMJ. 2013; 347: f4151
        • Amsterdam E.A.
        • Wenger N.K.
        • Brindis R.G.
        • et al.
        2014 AHA/ACC guideline for the management of patients with non-ST-elevation acute coronary syndromes: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines.
        J Am Coll Cardiol. 2014; 64: e139-e228
        • Colleran R.
        • Kastrati A.
        Percutaneous coronary intervention: balloons, stents and scaffolds.
        Clin Res Cardiol. 2018; 107: 55-63
        • Bae E.H.
        • Lim S.Y.
        • Choi Y.H.
        • et al.
        Drug-eluting vs. bare-metal stents for treatment of acute myocardial infarction with renal insufficiency. Results from Korea Acute Myocardial Infarction Registry.
        Circ J. 2011; 75: 2798-2804
        • Tsai T.T.
        • Messenger J.C.
        • Brennan J.M.
        • et al.
        Safety and efficacy of drug-eluting stents in older patients with chronic kidney disease: a report from the linked CathPCI RegistryCMS claims database.
        J Am Coll Cardiol. 2011; 58: 1859-1869
        • Green S.M.
        • Selzer F.
        • Mulukutla S.R.
        • et al.
        Comparison of bare-metal and drug-eluting stents in patients with chronic kidney disease (from the NHLBI Dynamic Registry).
        Am J Cardiol. 2011; 108: 1658-1664
        • Saltzman A.J.
        • Stone G.W.
        • Claessen B.E.
        • et al.
        Long-term impact of chronic kidney disease in patients with ST-segment elevation myocardial infarction treated with primary percutaneous coronary intervention: the HORIZONS-AMI (Harmonizing Outcomes With Revascularization and Stents in Acute Myocardial Infarction) trial.
        JACC Cardiovasc Interv. 2011; 4: 1011-1019
        • Volodarskiy A.
        • Kumar S.
        • Pracon R.
        • et al.
        Drug-eluting vs bare-metal stents in patients with chronic kidney disease and coronary artery disease: insights from a systematic review and meta-analysis.
        J Inv Cardiol. 2018; 30: 10-17
        • Azzalini L.
        • Ojeda S.
        • Demir O.M.
        • et al.
        Recanalization of chronic total occlusions in patients with vs. without chronic kidney disease: the impact of contrast-induced acute kidney injury.
        Can J Cardiol. 2018; 34: 1275-1282
        • Har B.J.
        • James M.T.
        Assessing benefit vs risk of complex percutaneous coronary intervention in people with chronic kidney disease.
        Can J Cardiol. 2018; 34: 1244-1246
        • Medi C.
        • Montalescot G.
        • Budaj A.
        • et al.
        Reperfusion in patients with renal dysfunction after presentation with ST-segment elevation or left bundle branch block. GRACE (Global Registry of Acute Coronary Events).
        JACC Cardiovasc Interv. 2009; 2: 26-33
        • Medi C.
        • Chew D.P.B.
        • Amerena J.
        • et al.
        An invasive management strategy is associated with improved outcomes in high-risk acute coronary syndromes in patients with chronic kidney disease.
        Intern Med J. 2011; 41: 743-750
        • Lau J.K.
        • Anastasius M.O.
        • Hyun K.K.
        • et al.
        Evidence-based care in a population with chronic kidney disease and acute coronary syndrome. Findings from the Australian Cooperative National Registry of Acute Coronary Care, Guideline Adherence and Clinical Events (CONCORDANCE).
        Am Heart J. 2015; 170 (566-72.e561)
        • Neumann F.J.
        • Sousa-Uva M.
        • Ahlsson A.
        • et al.
        2018 ESC/EACTS guidelines on myocardial revascularization.
        Eur Heart J. 2019; 40: 87-165
        • Fitchett D.H.
        • Theroux P.
        • Brophy J.M.
        • et al.
        Assessment and management of acute coronary syndromes (ACS): a Canadian perspective on current guideline-recommended treatment - part 1: non-ST-segment elevation.
        ACS. Can J Cardiol. 2011; 27: S387-S401
        • Pasceri V.
        • Patti G.
        • Pelliccia F.
        • et al.
        Complete revascularization during primary percutaneous coronary intervention reduces death and myocardial infarction in patients with multivessel disease: meta-analysis and meta-regression of randomized trials.
        JACC Cardiovasc Interv. 2018; 11: 833-843
        • Thiele H.
        • Akin I.
        • Sandri M.
        • et al.
        PCI strategies in patients with acute myocardial infarction and cardiogenic shock.
        N Engl J Med. 2017; 377: 2419-2432
        • Murphy S.W.
        • Barrett B.J.
        • Parfrey P.S.
        Contrast nephropathy.
        J Am Soc Nephrol. 2000; 11: 177-182
        • Kellum J.A.
        • Lameire N.
        • Aspelin P.
        • et al.
        KDIGO clinical practice guideline for acute kidney injury.
        Kidney Int Suppl (2011). 2012; 2: 1-138
        • Azzalini L.
        • Spagnoli V.
        • Ly H.Q.
        Contrast-induced nephropathy: from pathophysiology to preventive strategies.
        Can J Cardiol. 2016; 32: 247-255
        • Mehran R.
        • Nikolsky E.
        Contrast-induced nephropathy: definition, epidemiology, and patients at risk.
        Kidney Int Suppl. 2006; : S11-S15
        • Amin A.P.
        • Salisbury A.C.
        • McCullough P.A.
        • et al.
        Trends in the incidence of acute kidney injury in patients hospitalized with acute myocardial infarction.
        Arch Intern Med. 2012; 172: 246-253
        • Brown J.R.
        • Malenka D.J.
        • DeVries J.T.
        • et al.
        Transient and persistent renal dysfunction are predictors of survival after percutaneous coronary intervention: insights from the Dartmouth Dynamic Registry.
        Catheter Cardiovasc Interv. 2008; 72: 347-354
        • Abe M.
        • Morimoto T.
        • Nakagawa Y.
        • et al.
        Impact of transient or persistent contrast-induced nephropathy on long-term mortality after elective percutaneous coronary intervention.
        Am J Cardiol. 2017; 120: 2146-2153
        • Mehran R.
        • Aymong E.D.
        • Nikolsky E.
        • et al.
        A simple risk score for prediction of contrast-induced nephropathy after percutaneous coronary intervention: development and initial validation.
        J Am Coll Cardiol. 2004; 44: 1393-1399
        • Ohno Y.
        • Maekawa Y.
        • Miyata H.
        • et al.
        Impact of periprocedural bleeding on incidence of contrast-induced acute kidney injury in patients treated with percutaneous coronary intervention.
        J Am Coll Cardiol. 2013; 62: 1260-1266
        • Aspelin P.
        • Aubry P.
        • Fransson S.G.
        • et al.
        Nephrotoxic effects in high-risk patients undergoing angiography.
        N Engl J Med. 2003; 348: 491-499
        • Solomon R.J.
        • Natarajan M.K.
        • Doucet S.
        • et al.
        Cardiac Angiography in Renally Impaired Patients (CARE) study: a randomized double-blind trial of contrast-induced nephropathy in patients with chronic kidney disease.
        Circulation. 2007; 115: 3189-3196
        • Jo S.H.
        • Youn T.J.
        • Koo B.K.
        • et al.
        Renal toxicity evaluation and comparison between visipaque (iodixanol) and hexabrix (ioxaglate) in patients with renal insufficiency undergoing coronary angiography: the RECOVER study: a randomized controlled trial.
        J Am Coll Cardiol. 2006; 48: 924-930
        • Marenzi G.
        • Assanelli E.
        • Campodonico J.
        • et al.
        Contrast volume during primary percutaneous coronary intervention and subsequent contrast-induced nephropathy and mortality.
        Ann Intern Med. 2009; 150: 170-177
        • Azzalini L.
        • Candilio L.
        • McCullough P.A.
        • Colombo A.
        Current risk of contrast-induced acute kidney injury after coronary angiography and intervention: a reappraisal of the literature.
        Can J Cardiol. 2017; 33: 1225-1228
        • Brown J.R.
        • MacKenzie T.A.
        • Maddox T.M.
        • et al.
        Acute kidney injury risk prediction in patients undergoing coronary angiography in a national Veterans Health Administration cohort with external validation.
        J Am Heart Assoc. 2015; 4e002136
        • Tsai T.T.
        • Patel U.D.
        • Chang T.I.
        • et al.
        Validated contemporary risk model of acute kidney injury in patients undergoing percutaneous coronary interventions: insights from the National Cardiovascular Data Registry Cath-PCI Registry.
        J Am Heart Assoc. 2014; 3e001380
        • Allen D.W.
        • Ma B.
        • Leung K.C.
        • et al.
        Risk prediction models for contrast-induced acute kidney injury accompanying cardiac catheterization: systematic review and meta-analysis.
        Can J Cardiol. 2017; 33: 724-736
        • Mueller C.
        • Buerkle G.
        • Buettner H.J.
        • et al.
        Prevention of contrast media-associated nephropathy: randomized comparison of 2 hydration regimens in 1620 patients undergoing coronary angioplasty.
        Arch Intern Med. 2002; 162: 329-336
        • Merten G.J.
        • Burgess W.P.
        • Gray L.V.
        • et al.
        Prevention of contrast-induced nephropathy with sodium bicarbonate: a randomized controlled trial.
        JAMA. 2004; 291: 2328-2334
        • Brar S.S.
        • Shen A.Y.J.
        • Jorgensen M.B.
        • et al.
        Sodium bicarbonate vs sodium chloride for the prevention of contrast medium-induced nephropathy in patients undergoing coronary angiography: a randomized trial.
        JAMA. 2008; 300: 1038-1046
        • Nijssen E.C.
        • Rennenberg R.J.
        • Nelemans P.J.
        • et al.
        Prophylactic hydration to protect renal function from intravascular iodinated contrast material in patients at high risk of contrast-induced nephropathy (AMACING): a prospective, randomised, phase 3, controlled, open-label, non-inferiority trial.
        Lancet. 2017; 389: 1312-1322
        • Weisbord S.D.
        • Gallagher M.
        • Jneid H.
        • et al.
        Outcomes after angiography with sodium bicarbonate and acetylcysteine.
        N Engl J Med. 2018; 378: 603-614
        • Brar S.S.
        • Aharonian V.
        • Mansukhani P.
        • et al.
        Haemodynamic-guided fluid administration for the prevention of contrast-induced acute kidney injury: the POSEIDON randomised controlled trial.
        Lancet. 2014; 383: 1814-1823
        • Giacoppo D.
        • Gargiulo G.
        • Buccheri S.
        • et al.
        Preventive strategies for contrast-induced acute kidney injury in patients undergoing percutaneous coronary procedures: evidence from a hierarchical bayesian network meta-analysis of 124 trials and 28 240 patients.
        Circ Cardiovasc Interv. 2017; 10e004383
        • Verhulst A.
        • D’Haese P.C.
        • De Broe M.E.
        Inhibitors of HMG-CoA reductase reduce receptor-mediated endocytosis in human kidney proximal tubular cells.
        J Am Soc Nephrol. 2004; 15: 2249-2257
        • Singh N.
        • Lee J.Z.
        • Huang J.J.
        • et al.
        Benefit of statin pretreatment in prevention of contrast-induced nephropathy in different adult patient population: systematic review and meta-analysis.
        Open Heart. 2014; 1e000127
        • Karimi Galougahi K.
        • Mintz G.S.
        • Karmpaliotis D.
        • Ali Z.A.
        Zero-contrast percutaneous coronary intervention on calcified lesions facilitated by rotational atherectomy.
        Catheter Cardiovasc Interv. 2017; 90: E85-E89
        • Ali Z.A.
        • Karimi Galougahi K.
        • Nazif T.
        • et al.
        Imaging- and physiology-guided percutaneous coronary intervention without contrast administration in advanced renal failure: a feasibility, safety, and outcome study.
        Eur Heart J. 2016; 37: 3090-3095
        • Mariani J.
        • Guedes C.
        • Soares P.
        • et al.
        Intravascular ultrasound guidance to minimize the use of iodine contrast in percutaneous coronary intervention: the MOZART (Minimizing cOntrast utiliZation With IVUS Guidance in coRonary angioplasTy) randomized controlled trial.
        JACC Cardiovasc Interv. 2014; 7: 1287-1293
        • Tunuguntla A.
        • Daneault B.
        • Kirtane A.J.
        Novel use of the GuideLiner catheter to minimize contrast use during PCI in a patient with chronic kidney disease.
        Catheter Cardiovasc Interv. 2012; 80: 453-455
        • Mamas M.A.
        • Fath-Ordoubadi F.
        • Fraser D.G.
        Telescoping catheter technique: looking towards the kidneys.
        Cardiovasc Revasc Med. 2011; 12: 123-128
        • Call J.
        • Sacrinty M.
        • Applegate R.
        • et al.
        Automated contrast injection in contemporary practice during cardiac catheterization and PCI: effects on contrast-induced nephropathy.
        J Invasive Cardiol. 2006; 18: 469-474
        • Azzalini L.
        • Mitomo S.
        • Hachinohe D.
        • Regazzoli D.
        • Colombo A.
        Zero-contrast percutaneous coronary intervention guided by dextran-based optical coherence tomography.
        Can J Cardiol. 2018; 34 (342.e341-3)
        • Mailloux L.
        • Swartz C.D.
        • Capizzi R.
        • et al.
        Acute renal failure after administration of low-molecular weight dextran.
        N Engl J Med. 1967; 277: 1113-1118
        • Ferraboli R.
        • Malheiro P.S.
        • Abdulkader R.C.
        • et al.
        Anuric acute renal failure caused by dextran 40 administration.
        Ren Fail. 1997; 19: 303-306
        • Flaherty M.P.
        • Pant S.
        • Patel S.V.
        • et al.
        Hemodynamic support with a microaxial percutaneous left ventricular assist device (Impella) protects against acute kidney injury in patients undergoing high-risk percutaneous coronary intervention.
        Circ Res. 2017; 120: 692-700
        • Holzmann M.J.
        • Hammar N.
        • Ahnve S.
        • et al.
        Renal insufficiency and long-term mortality and incidence of myocardial infarction in patients undergoing coronary artery bypass grafting.
        Eur Heart J. 2007; 28: 865-871
        • Noyez L.
        • Plesiewicz I.
        • Verheugt F.W.A.
        Estimated creatinine clearance instead of plasma creatinine level as prognostic test for postoperative renal function in patients undergoing coronary artery bypass surgery.
        Eur J Cardiothorac Surg. 2006; 29: 461-465
        • Cooper W.A.
        • O’Brien S.M.
        • Thourani V.H.
        • et al.
        Impact of renal dysfunction on outcomes of coronary artery bypass surgery: results from the Society of Thoracic Surgeons National Adult Cardiac Database.
        Circulation. 2006; 113: 1063-1070
        • Lok C.E.
        • Austin P.C.
        • Wang H.
        • Tu J.V.
        Impact of renal insufficiency on short- and long-term outcomes after cardiac surgery.
        Am Heart J. 2004; 148: 430-438
        • United States Renal Data System (USRD) group
        Cardiovascular special studies.
        Am J Kidney Dis. 2003; 41: S165-S176
        • Patel M.R.
        • Calhoon J.H.
        • Dehmer G.J.
        • et al.
        ACC/AATS/AHA/ASE/ASNC/SCAI/SCCT/STS 2017 appropriate use criteria for coronary revascularization in patients with stable ischemic heart disease.
        J Am Coll Cardiol. 2017; 69: 2212-2241
        • Gaudino M.
        • Serricchio M.
        • Luciani N.
        • et al.
        Risks of using internal thoracic artery grafts in patients in chronic hemodialysis via upper extremity arteriovenous fistula.
        Circulation. 2003; 107: 2653-2655
        • Hu J.
        • Chen R.
        • Liu S.
        • et al.
        Global incidence and outcomes of adult patients with acute kidney injury after cardiac surgery: a systematic review and meta-analysis.
        J Cardiothorac Vasc Anesth. 2016; 30: 82-89
        • Sellke F.W.
        • DiMaio J.M.
        • Caplan L.R.
        • et al.
        Comparing on-pump and off-pump coronary artery bypass grafting: numerous studies but few conclusions: a scientific statement from the American Heart Association council on cardiovascular surgery and anesthesia in collaboration with the interdisciplinary working group on quality of care and outcomes research.
        Circulation. 2005; 111: 2858-2864
        • Wang Y.
        • Zhu S.
        • Gao P.
        • Zhou J.
        • Zhang Q.
        Off-pump vs on-pump coronary surgery in patients with chronic kidney disease: a meta-analysis.
        Clin Exp Nephrol. 2018; 22: 99-109
        • Chukwuemeka A.
        • Weisel A.
        • Maganti M.
        • et al.
        Renal dysfunction in high-risk patients after on-pump and off-pump coronary artery bypass surgery: a propensity score analysis.
        Ann Thorac Surg. 2005; 80: 2148-2153
        • Sajja L.R.
        • Mannam G.
        • Chakravarthi R.M.
        • et al.
        Coronary artery bypass grafting with or without cardiopulmonary bypass in patients with preoperative non-dialysis dependent renal insufficiency: a randomized study.
        J Thorac Cardiovasc Surg. 2007; 133: 378-388
        • Chan W.
        • Ivanov J.
        • Ko D.
        • et al.
        Clinical outcomes of treatment by percutaneous coronary intervention vs coronary artery bypass graft surgery in patients with chronic kidney disease undergoing index revascularization in Ontario.
        Circ Cardiovasc Interv. 2015; 8: 1-10
        • Bangalore S.
        • Guo Y.
        • Samadashvili Z.
        • et al.
        Revascularization in patients with multivessel coronary artery disease and chronic kidney disease everolimus-eluting stents vs coronary artery bypass graft surgery.
        J Am Coll Cardiol. 2015; 66: 1209-1220
        • Wang Z.J.
        • Zhou Y.J.
        • Liu Y.Y.
        • et al.
        Comparison of drug-eluting stents and coronary artery bypass grafting for the treatment of multivessel coronary artery disease in patients with chronic kidney disease.
        Circ J. 2009; 73: 1228-1234
        • Chang T.I.
        • Shilane D.
        • Kazi D.S.
        • et al.
        Multivessel coronary artery bypass grafting vs percutaneous coronary intervention in ESRD.
        J Am Soc Nephrol. 2012; 23: 2042-2049
        • Milojevic M.
        • Head S.J.
        • Mack M.J.
        • et al.
        The impact of chronic kidney disease on outcomes following percutaneous coronary intervention vs coronary artery bypass grafting in patients with complex coronary artery disease: five-year follow-up of the SYNTAX trial.
        EuroIntervention. 2018; 14: 102-111
        • Giustino G.
        • Mehran R.
        • Serruys P.W.
        • et al.
        Left main revascularization with PCI or CABG in patients with chronic kidney disease: EXCEL trial.
        J Am Coll Cardiol. 2018; 72: 754-765
        • Charytan D.M.
        • Yang S.S.
        • McGurk S.
        • Rawn J.
        Long- and short-term outcomes following coronary artery bypass grafting in patients with and without chronic kidney disease.
        Nephrol Dial Transplant. 2010; 25: 3654-3663
        • Savi P.
        • Pereillo J.M.
        • Uzabiaga M.F.
        • et al.
        Identification and biological activity of the active metabolite of clopidogrel.
        Thromb Haemost. 2000; 84: 891-896
        • Small D.S.
        • Wrishko R.E.
        • Ernest C.S.
        • et al.
        Prasugrel pharmacokinetics and pharmacodynamics in subjects with moderate renal impairment and end-stage renal disease.
        J Clin Pharm Ther. 2009; 34: 585-594
        • Anderson S.D.
        • Shah N.K.
        • Yim J.
        • Epstein B.J.
        Efficacy and safety of ticagrelor: a reversible P2Y12 receptor antagonist.
        Ann Pharmacother. 2010; 44: 524-537
        • James S.
        • Budaj A.
        • Aylward P.
        • et al.
        Ticagrelor vs clopidogrel in acute coronary syndromes in relation to renal function: results from the Platelet Inhibition and Patient Outcomes (PLATO) trial.
        Circulation. 2010; 122: 1056-1067
        • Summaria F.
        • Giannico M.B.
        • Talarico G.P.
        • Patrizi R.
        Antiplatelet therapy in hemodialysis patients undergoing percutaneous coronary interventions.
        Nephrourol Mon. 2015; 7e28099
        • Kasiske B.L.
        • Cangro C.B.
        • Hariharan S.
        • et al.
        The evaluation of renal transplant candidates: clinical practice guidelines.
        Am J Transplant. 2001; 2: 5-95
        • Tonelli M.
        • Karumanchi S.A.
        • Thadhani R.
        Epidemiology and mechanisms of uremia-related cardiovascular disease.
        Circulation. 2016; 133: 518-536
        • Knoll G.
        • Cockfield S.
        • Blydt-Hansen T.
        • et al.
        Canadian Society of Transplantation: consensus guidelines on eligibility for kidney transplantation.
        CMAJ. 2005; 173: S1-S25
        • Gill J.S.
        • Ma I.
        • Landsberg D.
        • Johnson N.
        • Levin A.
        Cardiovascular events and investigation in patients who are awaiting cadaveric kidney transplantation.
        J Am Soc Nephrol. 2005; 16: 808-816
        • Manske C.L.
        • Wang Y.
        • Rector T.
        • Wilson R.F.
        • White C.W.
        Coronary revascularisation in insulin-dependent diabetic patients with chronic renal failure.
        Lancet. 1992; 340: 998-1002
        • Rathore S.
        Small coronary vessel angioplasty: outcomes and technical considerations.
        Vasc Health Risk Manag. 2010; 6: 915-922
        • Lenihan C.R.
        • Montez-Rath M.E.
        • Winkelmayer W.C.
        • Chang T.I.
        Multivessel coronary revascularization and outcomes in kidney transplant recipients.
        Transplant Int. 2013; 26: 1080-1087
        • Ojo A.O.
        Cardiovascular complications after renal transplantation and their prevention.
        Transplantation. 2006; 82: 603-611
        • Hlatky M.A.
        • Boothroyd D.B.
        • Bravata D.M.
        • et al.
        Coronary artery bypass surgery compared with percutaneous coronary interventions for multivessel disease: a collaborative analysis of individual patient data from ten randomised trials.
        Lancet. 2009; 373: 1190-1197
        • Ramsdale D.R.
        • Bellamy C.M.
        Management of atrial exit block during physiological pacing for cardiogenic shock post myocardial infarction.
        Pacing Clin Electrophysiol. 1990; 13: 821-822
        • Fihn S.D.
        • Blankenship J.C.
        • Alexander K.P.
        • et al.
        2014 ACC/AHA/AATS/PCNA/SCAI/STS focused update of the guideline for the diagnosis and management of patients with stable ischemic heart disease: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines, and the American Association for Thoracic Surgery, Preventive Cardiovascular Nurses Association, Society for Cardiovascular Angiography and Interventions, and Society of Thoracic Surgeons.
        Circulation. 2014; 130: 1749-1767